An Update on the Current State of Management and Clinical Trials for IgA Nephropathy

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Jul 2

PMID 34200024

Citations 23

Authors

Chee Kay Cheung

Arun Rajasekaran

Jonathan Barratt

Dana V Rizk

Affiliations

Soon will be listed here.

Abstract

IgA nephropathy remains the most common primary glomerular disease worldwide. It affects children and adults of all ages, and is a leading cause of end-stage kidney disease, making it a considerable public health issue in many countries. Despite being initially described over 50 years ago, there are still no disease specific treatments, with current management for most patients being focused on lifestyle measures and renin-angiotensin-aldosterone system blockade. However, significant advances in the understanding of its pathogenesis have been made particularly over the past decade, leading to great interest in developing new therapeutic strategies, and a significant rise in the number of interventional clinical trials being performed. In this review, we will summarise the current state of management of IgAN, and then describe major areas of interest where new therapies are at their most advanced stages of development, that include the gut mucosal immune system, B cell signalling, the complement system and non-immune modulators. Finally, we describe clinical trials that are taking place in each area and explore future directions for translational research.

Citing Articles

Real-world assessment of sparsentan's drug safety framework.

Fu W, Wang J, Xue Y, Pan D Ren Fail. 2025; 47(1):2461668.

PMID: 39972562 PMC: 11843636. DOI: 10.1080/0886022X.2025.2461668.

HDAC9-mediated deacetylation of CALML6 promotes excessive proliferation of glomerular mesangial cells in IgA nephropathy.

Zhuang X, Xiao F, Chen F, Ni S Clin Exp Nephrol. 2025; .

PMID: 39833449 DOI: 10.1007/s10157-024-02620-5.

Systematic review of the application of the Kidney Failure Risk Equation and Oxford classification in estimating prognosis in IgA Nephropathy.

Toal M, Fergie R, Quinn M, Hill C, ONeill C, Maxwell A Syst Rev. 2025; 14(1):16.

PMID: 39819700 PMC: 11737263. DOI: 10.1186/s13643-024-02739-2.

Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.

Regalia A, Abinti M, Alfieri C, Campise M, Verdesca S, Zanoni F Clin Kidney J. 2024; 17(12):sfae320.

PMID: 39664990 PMC: 11630810. DOI: 10.1093/ckj/sfae320.

State-of-Art Therapeutics in IgA Nephropathy.

Mathur M, Sahay M, Pereira B, Rizk D Indian J Nephrol. 2024; 34(5):417-430.

PMID: 39372635 PMC: 11450772. DOI: 10.25259/ijn_319_23.

References

Jennette J . The immunohistology of IgA nephropathy. Am J Kidney Dis. 1988; 12(5):348-52. DOI: 10.1016/s0272-6386(88)80022-2. View

Selvaskandan H, Cheung C, Dormer J, Wimbury D, Martinez M, Xu G . Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis. Nephron. 2020; 144(9):453-458. DOI: 10.1159/000508841. View

Goto T, Bandoh N, Yoshizaki T, Nozawa H, Takahara M, Ueda S . Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy. Clin Immunol. 2008; 126(3):260-9. DOI: 10.1016/j.clim.2007.11.003. View

Wyatt R, Julian B . IgA nephropathy. N Engl J Med. 2013; 368(25):2402-14. DOI: 10.1056/NEJMra1206793. View

Allen A, Bailey E, Brenchley P, Buck K, Barratt J, Feehally J . Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int. 2001; 60(3):969-73. DOI: 10.1046/j.1523-1755.2001.060003969.x. View

Wyatt R, Kanayama Y, Julian B, Negoro N, Sugimoto S, Hudson E . Complement activation in IgA nephropathy. Kidney Int. 1987; 31(4):1019-23. DOI: 10.1038/ki.1987.101. View

Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H . Effect of a specific endothelin receptor A antagonist on glomerulonephritis of ddY mice with IgA nephropathy. Nephron. 1996; 72(3):454-60. DOI: 10.1159/000188912. View

Daha M, van Kooten C . Role of complement in IgA nephropathy. J Nephrol. 2015; 29(1):1-4. PMC: 4733139. DOI: 10.1007/s40620-015-0245-6. View

Rosenblad T, Rebetz J, Johansson M, Bekassy Z, Sartz L, Karpman D . Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol. 2014; 29(11):2225-8. DOI: 10.1007/s00467-014-2863-y. View

10.

Pozzi C, Bolasco P, Fogazzi G, Andrulli S, Altieri P, Ponticelli C . Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353(9156):883-7. DOI: 10.1016/s0140-6736(98)03563-6. View

11.

Clarkson A, Seymour A, Thompson A, Haynes W, Chan Y, Jackson B . IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. Clin Nephrol. 1977; 8(5):459-71. View

12.

Allen A, Harper S, Feehally J . Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995; 100(3):470-4. PMC: 1534466. DOI: 10.1111/j.1365-2249.1995.tb03724.x. View

13.

Fellstrom B, Barratt J, Cook H, Coppo R, Feehally J, De Fijter J . Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017; 389(10084):2117-2127. DOI: 10.1016/S0140-6736(17)30550-0. View

14.

Onda K, Ohsawa I, Ohi H, Tamano M, Mano S, Wakabayashi M . Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol. 2011; 12:64. PMC: 3283454. DOI: 10.1186/1471-2369-12-64. View

15.

Zhai Y, Zhu L, Shi S, Liu L, Lv J, Zhang H . Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy. Medicine (Baltimore). 2016; 95(11):e3099. PMC: 4839931. DOI: 10.1097/MD.0000000000003099. View

16.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

17.

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M . Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014; 46(11):1187-96. PMC: 4213311. DOI: 10.1038/ng.3118. View

18.

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M . After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020; 98(4):1044-1052. DOI: 10.1016/j.kint.2020.04.046. View

19.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

20.

Roos A, Rastaldi M, Calvaresi N, Oortwijn B, Schlagwein N, van Gijlswijk-Janssen D . Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006; 17(6):1724-34. DOI: 10.1681/ASN.2005090923. View